Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

Barclays lowered the firm’s price target on GSK (GSK) to 1,450 GBp from 1,550 GBp and keeps an Equal Weight rating on the shares.

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Jefferies lowered GSK (NYSE:GSK) to hold, citing a valuation disconnect between fundamentals and price. Jefferies said it ...

Barclays lowered the firm’s price target on GSK (GSK) to 1,450 GBp from 1,550 GBp and keeps an Equal Weight rating on the shares. TipRanks is the most comprehensive data set of sell side ...

pence - 'overweight' RBC cuts Howden Joinery price target to 930 (980) pence - 'sector perform' Barclays cuts GSK price target to 1,450 (1,550) pence - 'equal weight' Barclays cuts BT price target ...

GSK confirmed that the program is progressing to Phase 3 in ... as we drive forward our mission to develop transformative mRNA medicines and create long-term value for our shareholders." Cash and cash ...

GSK PLC (NYSE:GSK) by 182,429 shares, resulting in a -14.7% decrease in shares and a -1.18% impact on the portfolio. The ...

Furthermore, GSK is well known for providing its brand products with a price in Egypt that can be a fraction of its regular price in the region. Of the top 20 multinational corporations working in ...

The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...